FINWIRES · TerminalLIVE
FINWIRES

Trident Intersects Best Drill Results to Date at Contact Lake Project in Saskatchewan

作者

-- Trident Resources (ROCK.V) intersected its best drill result to date at the Contact Lake gold project in Saskatchewan, the company said Wednesday.

Trident drilled 15.11 grams per tonne (g/t) gold over 51.83 meters in hole CL26036, representing" a rare, high-grade result in Canadian gold exploration," the company said.

The company also reported high-grade gold values from a broad zone of variably sheared host rocks within and adjacent to the Bakos Shear Zone. Other results include 5.07 g/t gold over 21.50 meters.

"What makes these results particularly compelling is the fact that mineralization remains open in all directions, highlighting the significant growth potential we see across the system," Chief Executive Officer Jon Wiesblatt said.

"We are seeing high-grade gold associated with multiple, parallel shear zones in drilling which is exciting as the potential convergence of these zones at depth represents an untested high-priority drill target," Wiesblatt added.

An additional 15 drill holes are pending from Contact Lake, targeting the high-grade BK3 zone. The company also plans to conduct drill programs in summer and fall.

相关文章

Australia

Ryde与VinaTaxi签署谅解备忘录,探索越南市场机遇

Ryde集团(RYDE)周三宣布,已与VinaTaxi签署谅解备忘录,共同探索在越南的战略合作机会。 该公司表示,合作探索的领域包括在VinaTaxi的出租车车队中部署Ryde的平台,以及开发电动摩托车出行生态系统。Price: $1.20, Change: $+0.02, Percent Change: +1.61%

$RYDE
Australia

Emergent BioSolutions 签署价值 5000 万美元的合同,为 SAB Biotherapeutics 的领先项目提供支持

Emergent BioSolutions (EBS) 周三宣布,已与 SAB Biotherapeutics (SABS) 签署一项价值 5000 万美元的多年期协议,以推进 SAB-142 的临床开发,该药物用于治疗自身免疫性 1 型糖尿病。 根据协议,其中 3600 万美元的款项取决于未来的监管审批和后续里程碑的达成情况。 Emergent BioSolutions 表示,将提供符合现行良好生产规范 (cGMP) 的端到端开发和生产服务。Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS
Australia

Immunome公司提交了基于3期临床试验数据的Varegacestat新药申请。

Immunome(IMNM)周三宣布,已向美国食品药品监督管理局(FDA)提交了新药申请,申请上市的药物为varegacestat,一种用于治疗成人纤维瘤的在研口服药物。 该公司表示,此次申请基于积极的3期RINGSIDE试验结果,结果显示与安慰剂相比,varegacestat显著改善了患者的无进展生存期,降低了84%的疾病进展或死亡风险,客观缓解率达到56%。 该公司补充说,试验的详细数据将在2026年美国临床肿瘤学会(ASCO)年会上公布。 Immunome股价周三下跌2.7%。Price: $23.18, Change: $-0.53, Percent Change: -2.24%

$IMNM